These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33921064)

  • 1. Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology.
    Stergiou IE; Kambas K; Poulaki A; Giannouli S; Katsila T; Dimitrakopoulou A; Vidali V; Mouchtouris V; Kloukina I; Xingi E; Pagakis SN; Probert L; Patrinos GP; Ritis K; Tzioufas AG; Voulgarelis M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression significance and potential mechanism of hypoxia-inducible factor 1 alpha in patients with myelodysplastic syndromes.
    Liang HW; Luo B; Du LH; He RQ; Chen G; Peng ZG; Ma J
    Cancer Med; 2019 Oct; 8(13):6021-6035. PubMed ID: 31411003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
    Tong H; Hu C; Zhuang Z; Wang L; Jin J
    Leuk Lymphoma; 2012 Dec; 53(12):2412-8. PubMed ID: 22632108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
    Mpakou V; Spathis A; Bouchla A; Tsakiraki Z; Kontsioti F; Papageorgiou S; Bazani E; Gkontopoulos K; Thomopoulos T; Glezou I; Galanopoulos A; Symeonidis A; Diamantopoulos PT; Viniou NA; Kontandreopoulou CN; Zafeiropoulou K; Kotsianidis I; Lamprianidou E; Foukas P; Mpamias A; Pappa V
    Hematol Oncol; 2021 Apr; 39(2):231-242. PubMed ID: 33332639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes.
    Pribyl M; Hubackova S; Moudra A; Vancurova M; Polackova H; Stopka T; Jonasova A; Bokorova R; Fuchs O; Stritesky J; Salovska B; Bartek J; Hodny Z
    Mol Oncol; 2020 Oct; 14(10):2403-2419. PubMed ID: 32696549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow.
    Lévesque JP; Winkler IG; Hendy J; Williams B; Helwani F; Barbier V; Nowlan B; Nilsson SK
    Stem Cells; 2007 Aug; 25(8):1954-65. PubMed ID: 17478585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
    Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow.
    Pecci A; Travaglino E; Klersy C; Invernizzi R
    Acta Haematol; 2003; 109(1):29-34. PubMed ID: 12486320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities.
    Farha S; Asosingh K; Xu W; Sharp J; George D; Comhair S; Park M; Tang WH; Loyd JE; Theil K; Tubbs R; Hsi E; Lichtin A; Erzurum SC
    Blood; 2011 Mar; 117(13):3485-93. PubMed ID: 21258008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes.
    Hayashi Y; Zhang Y; Yokota A; Yan X; Liu J; Choi K; Li B; Sashida G; Peng Y; Xu Z; Huang R; Zhang L; Freudiger GM; Wang J; Dong Y; Zhou Y; Wang J; Wu L; Bu J; Chen A; Zhao X; Sun X; Chetal K; Olsson A; Watanabe M; Romick-Rosendale LE; Harada H; Shih LY; Tse W; Bridges JP; Caligiuri MA; Huang T; Zheng Y; Witte DP; Wang QF; Qu CK; Salomonis N; Grimes HL; Nimer SD; Xiao Z; Huang G
    Cancer Discov; 2018 Nov; 8(11):1438-1457. PubMed ID: 30139811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
    Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
    Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
    Font P; Subirá D; Matarraz S; Benavente C; Cedena MT; Morado M; Pérez Corral A; Bellón JM; Díez-Martín JL
    Cytometry B Clin Cytom; 2018 May; 94(3):527-535. PubMed ID: 28618451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of Qinghuang Powder combined Chinese herbs for Pi-strengthening and Shen-reinforcing on HIF-1alpha in bone marrow mononuclear cells of myelodysplastic syndrome patients: an experimental research].
    Gao F; Xu YG; Yang XH; Ma R
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Feb; 34(2):174-8. PubMed ID: 24672941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of Quantitative assessment of Myeloid Nuclear Differentiation Antigen expression and other flow cytometric parameters in the diagnosis of Myelodysplastic syndrome.
    Somasundaram V; Soni S; Chopra A; Rai S; Mahapatra M; Kumar R; Pati H
    Int J Lab Hematol; 2016 Apr; 38(2):141-50. PubMed ID: 26822549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced growth of myelodysplastic colonies in hypoxic conditions.
    Thompson JE; Conlon JP; Yang X; Sanchez PV; Carroll M
    Exp Hematol; 2007 Jan; 35(1):21-31. PubMed ID: 17198870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome.
    Schlesinger M; Silverman LR; Jiang JD; Yagi MJ; Holland JF; Bekesi JG
    J Clin Lab Immunol; 1996; 48(4):149-66. PubMed ID: 9819667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (MDS) through a single cell genomic study.
    Guo X; Jin W; Wen Y; Wang Z; Ren X; Liu Z; Fu R; Cai Z; Li L
    J Transl Med; 2024 Jul; 22(1):673. PubMed ID: 39033303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes.
    De Smet D; Trullemans F; Jochmans K; Renmans W; Smet L; Heylen O; Bael AM; Schots R; Leus B; De Waele M
    Am J Clin Pathol; 2012 Nov; 138(5):732-43. PubMed ID: 23086775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.